학술논문
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
Document Type
Article
Author
Source
In: Clinical Cancer Research . (Clinical Cancer Research, 15 January 2012, 18(2):555-567)
Subject
Language
English
ISSN
10780432
15573265
15573265